



# Together2Goal<sup>®</sup>

AMGA Foundation  
National Diabetes Campaign



# Monthly Campaign Webinar

## July 16, 2020

# Today's Webinar

- Together 2 Goal<sup>®</sup> Updates
  - Webinar Reminders
  - Innovator Track Eye Care Cohort Case Studies
  - Know Diabetes By Heart™ COVID-19 Resources
- Prediabetes Predictive Model—Delivering Patient-specific Risk Estimates at the Point-of-Care
  - Francis Colangelo, M.D., M.S.-HQS, FACP of Premier Medical Associates.
  - John Cuddeback, M.D., Ph.D. of AMGA Analytics
- Q&A
  - Use Q&A or chat feature



# Webinar Reminders

- Webinar will be recorded today and available the week of July 20<sup>th</sup>
  - [www.Together2Goal.org](http://www.Together2Goal.org)
- Participants are encouraged to ask questions using the “Chat” and “Q&A” functions on the right side of your screen




# Innovator Track Eye Care Cohort Case Studies



Now available at [www.together2goal.org](http://www.together2goal.org)

# Know Diabetes By Heart™ COVID-19 Resources



## [Practical Guide For Management of COVID-19 & Type 2 Diabetes](#)


# Today's Featured Presenter

Francis Colangelo, M.D.,  
M.S.-HQS, FACP



Chief Quality Officer  
Premier Medical Associates

John Cuddeback, M.D., Ph.D.



Chief Medical Informatics Officer  
AMGA



# Predictive Model for Prediabetes: Individual Risk Estimates and Benefit-Based Treatment

Francis Colangelo, MD, MS-HQS, FACP  
VP and Chief Quality Officer  
Premier Medical Associates

John Cuddeback, MD, PhD  
Chief Medical Informatics Officer  
AMGA

July 16, 2020



# Topics



- Why a predictive model for people with prediabetes?
- Reanalysis of a landmark clinical trial
  - Estimate risk for each individual, rather than an overall average
  - Adapt for clinical use
- Results from initial use for shared decision-making
- How can we make this easier to implement at other health systems?

# Topics



- Why a predictive model for people with prediabetes?
- Reanalysis of a landmark clinical trial
  - Estimate risk for each individual, rather than an overall average
  - Adapt for clinical use
- Results from initial use for shared decision-making
- How can we make this easier to implement at other health systems?



PCORI Predictive Analytics  
Resource Center (PARC)

# Together 2 Goal<sup>®</sup>

Improve care for  
**1 million** people with  
type 2 diabetes  
by 2021





## Together 2 Goal<sup>®</sup>

**1,082,000** patients, aged 18–89, with improved care  
2/3 with net improvement in control on campaign measures  
1/3 have new diagnosis—identified through screening



*Collective achievement of AMGA members participating in T2G<sup>®</sup> and reporting data quarterly, through year 3 of the campaign*

## 1 out of 4

people with type 2 diabetes  
don't know they have it!

*Early treatment is important,  
to minimize future complications*

## Survey of Together 2 Goal Participants

Which “planks” will you adopt?

31% said they *wouldn't* focus on screening

They were already overwhelmed by the number of people with type 2 diabetes  
...let alone prediabetes!

*For every person with a screening result in the diabetes range,  
6 people are identified who have prediabetes*



# What Is Prediabetes?

Elevated blood sugar, but not high enough to indicate diabetes

Elevated risk of developing type 2 diabetes over 3 years—about 29%

**84 million Americans have prediabetes—1 out of 3 adults**

Is there an effective way to prevent progression to diabetes?

Is there a way to prioritize—identify those at highest risk?

- Population level
- Patient level—shared decision-making

## Prediabetes Criteria (ADA 2020)

Fasting glucose	100–125 mg/dL
HbA1c	5.7 – 6.4%
2 hr OGTT	140–199 mg/dL

# Diabetes Prevention Program (DPP) Study



Randomized controlled trial

Participants: 3,060 non-diabetic adults at 27 centers, BMI  $\geq$  24 (or 22 if Asian) with both:

- Impaired glucose tolerance (140–199 mg/dL at 2 hr in a glucose tolerance test, 75 g glucose load)
- Impaired fasting glucose (95–125 mg/dL)

Main outcome measure: Development of diabetes over 3 years

Conducted 1996–2001, stopped early because the interventions were so effective

Three study arms:

No intervention (placebo) → **29% average risk** of developing diabetes over 3 years

Intensive lifestyle program (“DPP program”) → **average absolute risk reduction 14%**

Taking metformin (850 mg twice daily) → **average absolute risk reduction 7%**



# Topics



- Why a predictive model for people with prediabetes?
- Reanalysis of a landmark clinical trial
  - Estimate risk for each individual, rather than an overall average
  - Adapt for clinical use
- Results from initial use for shared decision-making
- How can we make this easier to implement at other health systems?

## Heterogeneity of Treatment Effect

*We tend to assume that anyone who would have qualified for a clinical trial will experience the average treatment effect seen in the trial*

But in most trials, some patients benefit, and some don't—heterogeneity of treatment effect

Can we predict, using information available at the beginning of the trial, the likelihood that an individual patient will benefit?

Population perspective → Can we risk-stratify?


At the outset, some patients are at higher risk of the outcome—heterogeneity of baseline risk

Likelihood of benefit from an intervention depends on individual's baseline risk for the outcome

# Distribution of Predicted Risk in DPP Study




Predictive model: risk of developing diabetes at 3 years, based on data available at the beginning of the study



Includes all participants in the DPP Study—  
placebo arm, plus both intervention arms.

c-statistic 0.73, indicating good discrimination

# Distribution of Predicted Risk in 32 Randomized Clinical Trials




Heterogeneity of baseline risk is common, often following a distribution similar to that seen in the DPP Study

Multiple models developed for some trials. See reference on previous slide.


# Absolute Risk Reduction Seen in DPP Study



### Intensive Lifestyle Intervention



### Metformin



From the predictive model

## Topics

- Why a predictive model for people with prediabetes?
- Reanalysis of a landmark clinical trial
  - Estimate risk for each individual, rather than an overall average
  - Adapt for clinical use
- Results from initial use for shared decision-making
- How can we make this easier to implement at other health systems?

# Re-develop Risk Model using Typical EHR Data



## Model from DPP Study Data

- HbA1c
- Fasting glucose
- Triglycerides
- History of elevated glucose
- Height
- Waist circumference
- Waist:hip ratio

Reflects tests currently used to detect prediabetes and diabetes

Accommodates missing data (imputed values for most model data elements)

## Adapted Model for Use in EHR

- HbA1c
- Fasting glucose
- Triglycerides
- Age
- Gender
- Race
- BMI
- Smoking status
- Systolic blood pressure
- Hypertension diagnosis
- HDL cholesterol (“good cholesterol”)



Longitudinal data for over 2 million people with prediabetes

# Use Model to Apply Learning from DPP Study in Current Practice



- Confirm that new EHR-based model works...
  - On a separate dataset representing current EHR data
  - On the placebo arm of the DPP Study (all the new variables were measured in the DPP Study)
- Then, for people with prediabetes, use this model to estimate their individual risk of developing type 2 diabetes over 3 years

**Multivariable model is a better predictor than any single parameter:**

In the lowest-risk quartile, about 15% of patients have  $A1c \geq 6.0$

In the highest-risk quartile, more than 25% of patients have  $A1c < 6.0$

- Apply risk-specific estimates of the effects of the two interventions in the DPP Study
  - Consistent benefit for the lifestyle program (58% *relative* risk reduction, across all levels of risk)
  - Benefit from taking metformin is concentrated in high-risk individuals



# Topics

- Why a predictive model for people with prediabetes?
- Reanalysis of a landmark clinical trial
  - Estimate risk for each individual, rather than an overall average
  - Adapt for clinical use
- Results from initial use for shared decision-making
- How can we make this easier to implement at other health systems?

# Premier Medical Associates


- Eastern suburbs of Pittsburgh, PA
- Formed 1993
- 100 providers
- Part of Highmark Health–Allegheny Health Network IDFS











“It now takes an average of 17 years for new knowledge generated by randomized controlled trials to be incorporated into practice, and even then, application is highly uneven.”

# The New England Journal of Medicine

Copyright © 2002 by the Massachusetts Medical Society

VOLUME 346

FEBRUARY 7, 2002

NUMBER 6



**REDUCTION IN THE INCIDENCE OF TYPE 2 DIABETES WITH LIFESTYLE  
INTERVENTION OR METFORMIN**

DIABETES PREVENTION PROGRAM RESEARCH GROUP\*

# Study Description

- ✓ 2 AMGA Member Organizations
- ✓ Patient Stakeholders
- ✓ Patient and Provider Focus Groups
- ✓ Patient and Provider Surveys



# Patient and Provider Focus Groups

## People with prediabetes want a personalized estimate

- Want to know *their* risk of diabetes
- Quoted ages when multiple family members developed type 2 diabetes

## Providers want guidance for shared decision-making

- Aware of DPP Study and “National DPP” offered locally by the “Y”
- Want to support and encourage patients—especially for the intensive lifestyle program
- Feel overwhelmed—need to prioritize



# Intensive Lifestyle Intervention

- ✓ DPP Programs are Resource-Intensive
  - 16 core sessions: one-to-one, in person
  - 2 monthly maintenance phone contacts
  - Exercise facilities at no cost
  
- ✓ For every 1 kg of weight loss, diabetes incidence drops by 16 percent.

# Utilization Savings

- ✓ CMS Office of the Actuary estimates \$2,650 in net cost savings for a Medicare beneficiary over 15 months, by participating in a DPP
- ✓ Intermountain: Avoiding or delaying progression to diabetes saves Intermountain's Health Plan \$3,500 per patient per year
- ✓ DPP participation costs about \$600

Data retrieved from EHR,  
displayed in the EHR for  
validation and editing  
by the clinician, at  
Premier Medical Associates

eCalcs add-in for  
Allscripts TouchWorks EHR



**Allscripts, Predm** MRN **2226800** H Phone **(412)457-0060** Home Chart **OFFICE IM ONE M**  
01-Jan-1962 (56y) F | **PCP Colangelo, Francis** FYI **FYI** Dash **Open**   
W Phone Pri Ins

**Tufts DPP Risk Estimator v20180418**

Search/Filter

- ASCVD Risk
- Caloric Requirements
- CHA2DS2-VASc for Risk of Stroke
- Creatinine Clearance
- D.I.R.E Score
- Final Parental Height (FPH) Child Height Predictor
- FRAX WHO Fracture Risk
- HAS-BLED
- LACE Index Scoring Tool
- MCHAT-R
- PHQ-A (PHQ-9 for Adolescents)
- Tufts DPP Risk Estimator**

Sex: Female

Race: Black

Smoking Status: Former Smoker

Hypertension: True

Metric  U.S.

Height: 64 in

Weight: 160 lb

BMI: 27.46 kg/m<sup>2</sup>

Systolic Blood Pressure: 138 mmHg

HDL Cholesterol: 38 mg/dL

Triglycerides: 180 mg/dL

A1C: 6.2 %

Fasting Blood Glucose: 118 mg/dL *Drawn in same timeframe as fasting labs, so assumed to be a fasting blood glucose.*

Calculate

Predictive model results,  
as displayed in the EHR for  
shared decision-making, at  
Premier Medical Associates

Interpretation: Low Risk Patient

Predicted Risk of Type 2 Diabetes at 3 Years	Treatment	Relative Risk Reduction (RRR)	Number Needed to Treat (NNT)
5.47 %	Usual Care	Reference	N/A
4.38 %	Metformin	20%	91.4
2.30 %	DPP Lifestyle	58%	31.5

Add to Chart

Predictive model results,  
as displayed in the EHR for  
shared decision-making, at  
Premier Medical Associates

Interpretation: Low Risk Patient

Predicted Risk of Type 2 Diabetes at 3 Years	Treatment	Relative Risk Reduction (RRR)	Number Needed to Treat (NNT)
5.47 %	Usual Care	Reference	N/A
4.38 %	Metformin	20%	91.4
2.30 %	DPP Lifestyle	58%	31.5

Add to Chart

Predictive model results,  
as displayed in the EHR for  
shared decision-making, at  
Premier Medical Associates

**Interpretation: Low Risk Patient**

<b>Predicted Risk of Type 2 Diabetes at 3 Years</b>	<b>Treatment</b>	<b>Relative Risk Reduction (RRR)</b>	<b>Number Needed to Treat (NNT)</b>
5.47 %	Usual Care	Reference	N/A
4.38 %	Metformin	20%	91.4
2.30 %	DPP Lifestyle	58%	31.5

[Add to Chart](#)



Predictive model results,  
as displayed in the EHR for  
shared decision-making, at  
Premier Medical Associates

**Interpretation: Low Risk Patient**

Predicted Risk of Type 2 Diabetes at 3 Years	Treatment	Relative Risk Reduction (RRR)	Number Needed to Treat (NNT)
5.47 %	Usual Care	Reference	N/A
4.38 %	Metformin	20%	91.4
2.30 %	DPP Lifestyle	58%	31.5

Add to Chart

**Interpretation: High Risk Patient**

Predicted Risk of Type 2 Diabetes at 3 Years	Treatment	Relative Risk Reduction (RRR)	Number Needed to Treat (NNT)
55.7 %	Usual Care	Reference	N/A
24.5 %	Metformin	56%	4
23.4 %	DPP Lifestyle	58%	4

Add to Chart

Predictive model results,  
as displayed in the EHR for  
shared decision-making, at  
Premier Medical Associates

Interpretation: Low Risk Patient

Predicted Risk of Type 2 Diabetes at 3 Years	Treatment	Relative Risk Reduction (RRR)	Number Needed to Treat (NNT)
5.47 %	Usual Care	Reference	N/A
4.38 %	Metformin	20%	91.4
2.30 %	DPP Lifestyle	58%	31.5

Add to Chart

Interpretation: High Risk Patient

Predicted Risk of Type 2 Diabetes at 3 Years	Treatment	Relative Risk Reduction (RRR)	Number Needed to Treat (NNT)
55.7 %	Usual Care	Reference	N/A
24.5 %	Metformin	56%	4
23.4 %	DPP Lifestyle	58%	4

Add to Chart



# PMA Experience—Reach of Project

	<b>5/1/18 – 8/31/19</b>
Total prediabetes	2,518
Calculation completed	1,881
Percent with calculation	74.7%

# Interventions vs. Risk

<b>Risk stratification</b>	<b>Intervention ordered</b>
High risk	75.2%
Medium risk	20.6%
Low risk	7.3%

# Interventions vs. Risk

Risk stratification	Intervention ordered
High risk	75.2%
Medium risk	20.6%
Low risk	7.3%

**During the 15 months, 97 patients were identified as having diabetes, through timely screening**

# Of the 901 high-risk patients...

41 were On Metformin before 5/1/2018

150 were Started on Metformin after 5/1/2018

0 were Referred to a DPP before 5/1/2018

487 were Referred to a DPP after 5/1/2018


# Patients Referred to YDPP

124 called the YMCA to inquire about program

64 actually enrolled

Average weight loss 17.8 pounds (7.4%)

# Provider Surveys: How confident are you in your ability to estimate the average risk of diabetes progression for your patients with prediabetes?



# Topics

- Why a predictive model for people with prediabetes?
- Reanalysis of a landmark clinical trial
  - Estimate risk for each individual, rather than an overall average
  - Adapt for clinical use
- Results from initial use for shared decision-making
- How can we make this easier to implement at other health systems?

# Personalized Risk Estimates at the Point of Care

*Two approaches to implementing the model in the EHR:*

## Build predictive model into EHR — Premier Medical Associates

- Calculator add-in for Allscripts TouchWorks: Galen eCalcs
- Provider needs to access the calculator, but eCalcs obtains data elements from patient’s record and displays them for validation or editing

## “Subscribe” to a cloud-hosted **SMART app**, using **FHIR resources** — Mercy

- Emerging EHR interoperability standards—Office of the National Coordinator for Health IT (ONC)
- EHR vendors are exposing data elements as “FHIR resources” and enabling integration of cloud-hosted apps
- **CDS Hooks** can trigger the calculation automatically, upon opening a patient’s record or posting a lab result that suggests prediabetes
- EHR vendors charge a small transaction fee, each time the model is used

EHR – Electronic health record (Premier uses Allscripts, with Galen eCalcs; Mercy uses Epic)

SMART – Substitutable Medical Apps and Reusable Technology

FHIR – Fast Healthcare Interoperability Resources, an HL7 standard

CDS Hooks – Clinical Decision Support Hooks




# SMART App

Cloud-hosted SMART app currently being implemented in Epic at Mercy

This is the **clinician view**, showing data values retrieved for this patient from the EHR, for validation/editing

Model results are displayed at the top of the screen



# SMART App

Cloud-hosted SMART app currently being implemented in Epic at Mercy

This is the **clinician view**, showing data values retrieved for this patient from the EHR, for validation/editing

Model results are displayed at the top of the screen

DPP lifestyle intervention yields a 12.0% absolute reduction in risk of diabetes at 3 years, from 20.6% to 8.6%, which corresponds to an NNT of 8

For this intermediate-risk patient, taking metformin yields only a 2.4% absolute reduction in risk, from 20.6% to 18.2%, which corresponds to an NNT of 36

MODEL
PATIENT VIEW
INFO

	20.6%	8.6%	18.2%
	3 years diabetes risk (usual care)	3 years diabetes risk (DPP lifestyle)	3 years diabetes risk (metformin)
Intermediate	-	58%	13.0%
Risk group	Relative risk reduction	Relative risk reduction (DPP lifestyle)	Relative risk reduction (metformin)
	-	8	36
	Number needed to treat	Number needed to treat (DPP lifestyle)	Number needed to treat (metformin)

---

### Patient data REFRESH RESET CREATE REPORT ?

**Age**  
56  
Value in EHR: 56

**Sex**  
 Male  
 Female

**Race**  
 White  
 Black  
 Asian  
 Missing

**Smoking Status**  
 Current  
 Former  
 Never  
 Missing

**Hypertension Dx**  
 Yes  
 No

▼ /  Reference EHR Values

**Body Mass Index (BMI) (kg/m<sup>2</sup>)**

Normal Overweight Obesity 1 Obesity 2 Obesity 3

**Systolic BP (mm Hg)**

Normal Elevated HTN Stage 1 HTN Stage 2

**HDL (good) cholesterol (mg/dL)**

**Triglycerides (mg/dL)**

**Fasting plasma glucose (mg/dL)**

**Hemoglobin A1c (%) - missing data**



# SMART App

Cloud-hosted SMART app currently being implemented in Epic at Mercy

This is the **clinician view**, showing data values retrieved for this patient from the EHR, for validation/editing

Model results are displayed at the top of the screen

Changing patient's race from missing to Black

MODEL
PATIENT VIEW
INFO

	24.6%	10.3%	19.5%
	3 years diabetes risk (usual care)	3 years diabetes risk (DPP lifestyle)	3 years diabetes risk (metformin)
Intermediate	-	58%	22.0%
Risk group	Relative risk reduction	Relative risk reduction (DPP lifestyle)	Relative risk reduction (metformin)
	-	7	19
	Number needed to treat	Number needed to treat (DPP lifestyle)	Number needed to treat (metformin)

---

### Patient data REFRESH RESET CREATE REPORT ?

**Age**  
56  
Value in EHR: 56

**Sex**  
 Male  
 Female

**Race**  
 White  
 Black  
 Asian  
 Missing

**Smoking Status**  
 Current  
 Former  
 Never  
 Missing

**Hypertension Dx**  
 Yes  
 No

Reference EHR Values

**Body Mass Index (BMI) (kg/m<sup>2</sup>)**

Normal Overweight Obesity 1 Obesity 2 Obesity 3

**Systolic BP (mm Hg)**

Normal Elevated HTN Stage 1 HTN Stage 2

**HDL (good) cholesterol (mg/dL)**

**Triglycerides (mg/dL)**

**Fasting plasma glucose (mg/dL)**

**Hemoglobin A1c (%) - missing data**



# SMART App

Cloud-hosted SMART app currently being implemented in Epic at Mercy

This is the **clinician view**, showing data values retrieved for this patient from the EHR, for validation/editing

Model results are displayed at the top of the screen

Changing patient's race from missing to Black Asian

MODEL
PATIENT VIEW
INFO

	24.4%	10.3%	19.0%
	3 years diabetes risk (usual care)	3 years diabetes risk (DPP lifestyle)	3 years diabetes risk (metformin)
Intermediate	-	58%	21.0%
Risk group	Relative risk reduction	Relative risk reduction (DPP lifestyle)	Relative risk reduction (metformin)
	-	7	20
	Number needed to treat	Number needed to treat (DPP lifestyle)	Number needed to treat (metformin)

---

### Patient data

REFRESH
RESET
CREATE REPORT
?

**Age**  
56  
Value in EHR: 56

**Sex**  
 Male  
 Female

**Race**  
 White  
 Black  
 Asian  
 Missing

**Smoking Status**  
 Current  
 Former  
 Never  
 Missing

**Hypertension Dx**  
 Yes  
 No

Reference EHR Values

**Body Mass Index (BMI) (kg/m<sup>2</sup>)**

Normal | Overweight | Obesity 1 | Obesity 2 | Obesity 3

**Systolic BP (mm Hg)**

Normal | Elevated | HTN Stage 1 | HTN Stage 2

**HDL (good) cholesterol (mg/dL)**

**Triglycerides (mg/dL)**

**Fasting plasma glucose (mg/dL)**

**Hemoglobin A1c (%) - missing data**




# SMART App

Cloud-hosted SMART app currently being implemented in Epic at Mercy

This is the **clinician view**, showing data values retrieved for this patient from the EHR, for validation/editing

Model results are displayed at the top of the screen

Changing patient's race from missing to Black  
Asian  
White



## Higher-risk Patient

Changing to a different patient, with a higher baseline risk

Same age, sex, race, smoking status, HTN  
Dx Higher BMI and systolic BP  
Lower HDL  
HbA1c 6.0% (instead of missing)

Since this patient is at a higher risk, there is more benefit from metformin than we saw with the intermediate-risk patient

High  
Risk group

31.9%

3 years diabetes risk (usual care)

-

Relative risk reduction

-

Number needed to treat

13.4%

3 years diabetes risk (DPP lifestyle)

58%

Relative risk reduction (DPP lifestyle)

5

Number needed to treat (DPP lifestyle)

21.4%

3 years diabetes risk (metformin)

33.0%

Relative risk reduction (metformin)

10

Number needed to treat (metformin)

### Patient data

REFRESH

RESET

CREATE REPORT



#### Age

56

Value in EHR: 56

 Reference EHR Values

#### Sex

 Male

 Female

#### Race

 White

 Black

 Asian

 Missing

#### Smoking Status

 Current

 Former

 Never

 Missing

#### Hypertension Dx

 Yes

 No

#### Body Mass Index (BMI) (kg/m<sup>2</sup>)



#### Systolic BP (mm Hg)



#### HDL (good) cholesterol (mg/dL)



#### Triglycerides (mg/dL)



#### Fasting plasma glucose (mg/dL)



#### Hemoglobin A1c (%)



## Higher-risk Patient

This is the **patient view**, displaying model results graphically, at the top of the screen

Sliders and radio buttons only for attributes that the patient might target changing, to explore “what-if” scenarios


But... Interpretation is important:

The updated model values correspond to putting the patient into a group of people with a different baseline risk and potentially a different estimated benefit from these interventions.

They do NOT reflect the prospective effect on the risk of diabetes if the patient were to make a change (e.g., stopping smoking, lowering blood pressure, or losing weight). That has not been studied.

You are in the **High** risk group

Risk of developing type 2 diabetes over the next 3 years:  
Among the highest-risk one-fourth of all people with pre-diabetes



### Patient data

[RESET](#)

#### Age

56

Value in EHR: 56

Reference EHR Values

#### Smoking Status

- Current
- Former
- Never
- Missing

Sex: Female

Race: White

Hypertension Dx: Yes

Fasting plasma glucose (mg/dL): 110

Hemoglobin A1c (%): 6.0

#### Body Mass Index (BMI) (kg/m<sup>2</sup>)



#### Systolic BP (mm Hg)



#### HDL (good) cholesterol (mg/dL)



#### Triglycerides (mg/dL)




# Higher-risk Patient

Exploring model behavior...

Former smoker, instead of current smoker

You are in the **High** risk group

Risk of developing type 2 diabetes over the next 3 years:  
Among the highest-risk one-fourth of all people with pre-diabetes



## Patient data

RESET

### Age

56

Value in EHR: 56

▼/○ Reference EHR Values

### Smoking Status

- Current
- Former
- Never
- Missing

Sex: Female

Race: White

Hypertension Dx: Yes

Fasting plasma glucose (mg/dL): 110

Hemoglobin A1c (%): 6.0

### Body Mass Index (BMI) (kg/m<sup>2</sup>)



### Systolic BP (mm Hg)



### HDL (good) cholesterol (mg/dL)



### Triglycerides (mg/dL)






# Higher-risk Patient

Exploring model behavior...

Former smoker, instead of current smoker  
Reduce BMI from 35 to 32 (8.6% weight loss)

You are in the **High** risk group

Risk of developing type 2 diabetes over the next 3 years:  
Among the highest-risk one-fourth of all people with pre-diabetes



## Patient data

RESET

### Age

56

Value in EHR: 56

▼/○ Reference EHR Values

### Smoking Status

- Current
- Former
- Never
- Missing

Sex: Female


Race: White

Hypertension Dx: Yes

Fasting plasma glucose (mg/dL): 110

Hemoglobin A1c (%): 6.0

### Body Mass Index (BMI) (kg/m<sup>2</sup>)



### Systolic BP (mm Hg)



### HDL (good) cholesterol (mg/dL)



### Triglycerides (mg/dL)




# Higher-risk Patient

Exploring model behavior...

Former smoker, instead of current smoker  
 Reduce BMI from 35 to 32 (8.6% weight loss)  
 Reduce systolic BP from 148 to 135

You are in the **High** risk group

Risk of developing type 2 diabetes over the next 3 years:  
 Among the highest-risk one-fourth of all people with pre-diabetes



## Patient data

RESET

### Age

56

Value in EHR: 56

▼/○ Reference EHR Values

### Smoking Status

- Current
- Former
- Never
- Missing

Sex: Female

Race: White

Hypertension Dx: Yes

Fasting plasma glucose (mg/dL): 110

Hemoglobin A1c (%): 6.0

### Body Mass Index (BMI) (kg/m<sup>2</sup>)



### Systolic BP (mm Hg)



### HDL (good) cholesterol (mg/dL)



### Triglycerides (mg/dL)



# Higher-risk Patient

Exploring model behavior...

Former smoker, instead of current smoker  
 Reduce BMI from 35 to 32 (8.6% weight loss)  
 Reduce systolic BP from 148 to 135  
 Reduce triglycerides from 200 to 175

These changes only reduce baseline risk from 31.9% to 28.1% (absolute  $\Delta$  3.8%, relative reduction of 11.9%)


For this patient's original parameters, DPP lifestyle reduces risk to 13.4% (absolute  $\Delta$  of 18.5%, relative 58%)

In most cases, the estimated benefit of the DPP lifestyle program substantially exceeds the change in baseline risk corresponding to the changes in parameters (weight loss, reduction in BP) that are typically achieved by participating in the program.

This may reflect the value of nutrition education, emphasis on exercise, and group activities. **For the DPP lifestyle program, the whole is more than the sum of its parts**

You are in the **High** risk group

Risk of developing type 2 diabetes over the next 3 years:  
 Among the highest-risk one-fourth of all people with pre-diabetes



## Patient data

RESET

### Age

56

Value in EHR: 56

Reference EHR Values

### Smoking Status

- Current
- Former
- Never
- Missing

Sex: Female

Race: White

Hypertension Dx: Yes

Fasting plasma glucose (mg/dL): 110

Hemoglobin A1c (%): 6.0

### Body Mass Index (BMI) (kg/m<sup>2</sup>)



### Systolic BP (mm Hg)



### HDL (good) cholesterol (mg/dL)



### Triglycerides (mg/dL)



In 2018, John Schultz talked to his doctor, Frank Colangelo, at Premier Medical Associates.

John learned he had prediabetes, and *his personal risk for developing diabetes* was high. That got his attention.

He took the DPP Lifestyle program seriously—healthy eating, getting more exercise. He lost over 30 pounds.

“I’ve had more energy, and I’m doing more things,” Schultz said. “From that meeting with Frank, it was a snowball effect.”



# August Webinar

- **Date/Time:** August 20, 2020  
from 2-3pm Eastern
- **Topic:** T2G Diabetes Bundle  
Best Practices Collaborative  
Results
- **Presenter:** AMGA



# Questions

